Calan (Verapamil): A Comprehensive Report on Its Uses, Mechanism, and Clinical Considerations > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Introduction

Calan is the brand name for verapamil, a medication belonging to the class of calcium channel blockers (CCBs). First approved by the U.S. Food and Drug Administration in 1981, verapamil has been widely used for decades in the management of cardiovascular conditions, including hypertension, angina pectoris, and certain cardiac arrhythmias. Unlike other CCBs, verapamil exerts significant effects on both vascular smooth muscle and cardiac conduction tissue, making it uniquely suited for rate control in supraventricular tachyarrhythmias. This report provides a concise overview of Calan’s pharmacology, therapeutic applications, adverse effects, and practical prescribing considerations.

Mechanism of Action

Verapamil selectively blocks L-type voltage-dependent calcium channels in the cell membranes of vascular smooth muscle and cardiac myocytes. By inhibiting calcium influx, it reduces intracellular calcium concentration, leading to relaxation of arterial smooth muscle (vasodilation) and a decrease in peripheral vascular resistance. In the heart, verapamil slows conduction through the atrioventricular (AV) node, prolongs the refractory period, and reduces myocardial contractility (negative inotropy). The net effect is a reduction in blood pressure, decreased myocardial oxygen demand, and control of ventricular rate in atrial fibrillation or flutter. Unlike dihydropyridine CCBs (e.g., nifedipine), verapamil has a more pronounced effect on cardiac conduction and is therefore classified as a non-dihydropyridine CCB.

Therapeutic Uses

1. Hypertension: Calan is effective as monotherapy or in combination with other antihypertensives. Its vasodilatory and mild diuretic effects help lower systolic and diastolic blood pressure. Extended-release formulations (Calan SR) provide once-daily dosing, improving adherence. However, verapamil is not typically first-line for hypertension unless there is a comorbid condition (e.g., angina or arrhythmia).
   
2. Angina Pectoris: Verapamil is indicated for chronic stable angina (effort-associated) as well as vasospastic angina (Prinzmetal’s). By reducing afterload and myocardial oxygen consumption, it improves exercise tolerance and decreases the frequency of anginal episodes. It is often used when beta-blockers are contraindicated or not tolerated.
   
3. Arrhythmias: Intravenous verapamil is a first-line agent for terminating acute episodes of paroxysmal supraventricular tachycardia (PSVT) involving reentry through the AV node. Oral verapamil is used for long-term rate control in atrial fibrillation or flutter, especially when digoxin is insufficient or when patients have concomitant hypertension. It is also used for prophylaxis of PSVT.
   
4. Off‑label uses: Verapamil has been investigated for migraine prophylaxis, cluster headaches, and hypertrophic cardiomyopathy, although these uses are less common and supported by variable evidence.
   
   

Verapamil is well absorbed orally but undergoes extensive first-pass hepatic metabolism, resulting in a bioavailability of only 20–35%. It is highly protein-bound (approx. 90%) and metabolized by the cytochrome P450 (CYP3A4) system. The half-life ranges from 3 to 7 hours with single doses but may increase with repeated administration (up to 12 hours). Extended-release formulations achieve steady-state concentrations over several days. Dose adjustments are necessary in patients with hepatic impairment or those taking inhibitors of CYP3A4 (e.g., erythromycin, ketoconazole).

Adverse Effects

The most common side effects are related to vasodilation: headache, dizziness, facial flushing, edema (ankle swelling), and constipation. Constipation is peculiarly frequent with verapamil (up to 10–15% of patients) due to inhibition of calcium-dependent smooth muscle activity in the gastrointestinal tract. More serious adverse effects include bradycardia, AV block (generally first-degree but can progress to higher degrees), and worsening heart failure in patients with preexisting left ventricular dysfunction. Verapamil can also cause gingival hyperplasia and, rarely, elevated liver enzymes. Hypersensitivity reactions are uncommon.

Drug Interactions

Verapamil is a substrate of CYP3A4 and also inhibits CYP3A4 and P-glycoprotein. Co-administration with beta-blockers (e.g., propranolol, metoprolol) can cause additive negative inotropic and chronotropic effects, leading to bradycardia, hypotension, or heart failure. It increases serum levels of digoxin, cyclosporine, statins (atorvastatin, simvastatin), and certain anticoagulants (dabigatran). Conversely, rifampin and phenytoin induce CYP3A4, reducing verapamil’s efficacy. Grapefruit juice also inhibits CYP3A4 and should be avoided.

Contraindications and Precautions

Calan is contraindicated in patients with severe left ventricular dysfunction (ejection fraction <30%), second- or third-degree AV block (unless a pacemaker is present), sick sinus syndrome, hypotension (systolic <90 mmHg), or atrial flutter/fibrillation associated with accessory bypass tracts (e.g., Wolff-Parkinson-White syndrome) because verapamil can accelerate conduction through the accessory pathway, risking ventricular fibrillation. Caution is needed in patients with liver disease, renal impairment (though dose adjustment is usually not required), and those already receiving negative inotropic agents.

Dosage Forms and Administration

Calan is available as immediate-release tablets (40 mg, 200mcg (http://braghette.it/) 80 mg, 120 mg) and extended-release (Calan SR) capsules (120 mg, 180 mg, 240 mg). For hypertension, the typical starting dose of Calan SR is 120–240 mg once daily. For arrhythmias, immediate-release verapamil 80–120 mg three or four times daily may be used, or intravenous administration of 2.5–10 mg over 2 minutes. The exact dose should be individualized based on response and tolerability.

Clinical Considerations and Monitoring

Before initiating therapy, clinicians should obtain baseline electrocardiogram (ECG) and assess for signs of heart failure. Periodic monitoring of heart rate and blood pressure is essential, especially during dose titration. In patients with atrial fibrillation, verapamil effectively controls ventricular rate but does not restore sinus rhythm. It is also important to note that verapamil may mask the symptoms of hyperthyroidism or hypoglycemia.

Conclusion

Calan (verapamil) remains a valuable medication in the management of hypertension, angina, and supraventricular arrhythmias. Its dual action on vascular and cardiac calcium channels differentiates it from other CCBs. However, clinicians must be vigilant regarding drug interactions, contraindications, and potential for bradyarrhythmias. When used appropriately, verapamil offers effective symptom control and cardiovascular risk reduction. As with all cardiovascular drugs, individual patient factors and comorbidities should guide therapy selection to maximize benefits while minimizing risks.